Ovation Science Receives its First Order from China for its DermSafe Hand Sanitizer to Help Combat Coronavirus


Ryan Allway

February 13th, 2020

News


Vancouver, British Columbia – (February 13, 2020) – Ovation Science Inc. (CSE: OVAT) (“Ovation” or the “Company”),  announces it has received an initial purchase order and full payment for 25,000 units of its DermSafe® hand sanitizer lotion made with chlorhexidine gluconate; an ingredient proven to be effective at killing both bacteria and viruses.

Ovation Science also announces it has entered into an extendable three year, exclusive world-wide licensing agreement with Skinvisible Pharmaceuticals, Inc. to manufacture, market and sell its DermSafe® hand sanitizer.

“We are selling our entire first batch of our DermSafe hand sanitizer to a significant Chinese entity, paid in full, and gearing up to fulfill what could be considerable demand, given the dire situation,” said Terry Howlett, President of Ovation. ”It is the first non-cannabis product distributed by Ovation Science, and it is an important one. DermSafe is proven to kill a host of bacteria and viruses, including envelope viruses and it provides an extra level of continued protection since it remains bound to the skin for up to four hours, resisting both wash-off and rub off. Although DermSafe has not been tested on the coronavirus (an envelope virus), viral studies conducted at one of Europe’s top virology labs demonstrates its effectiveness against other envelope viruses such as H5N1 (bird flu), H1N1 (swine flu) and H3N2 (influenza).”

The active ingredient in DermSafe, chlorhexidine gluconate, has been used in hospitals worldwide for over fifty years as a pre-surgical hand scrub due to its ability to kill both gram-negative and gram-positive bacteria and viruses.  The product does not contain alcohol and therefore is non-drying and does not have some of the issues that alcohol-based products do.  Visit https://ovationscience.com/products/ for more information.

The coronavirus (2019-nCoV also referred to as COVID-19), and its predecessors; severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), are all envelope viruses that have caused deaths in humans and infected thousands. Recently the goal to protect the public has escalated globally with the WHO (World Health Organization) declaring it a “public health emergency of international concern” particularly due to the accelerated spread of the coronavirus in China which has a population of almost 1.4 billion people. Ovation’s DermSafe® hand sanitizer is being shipped to China under a temporary “green channel” which facilitates foreign exchange of goods related to the fight against this epidemic.

According to a report from the WHO (World Health Organization) “Novel Coronavirus (2019-nCoV) Situation Report -21”, as of February 12, 2020 there were 45,171 confirmed cases of people with the Coronavirus in 24 countries however over 99% of cases are in China.  In China there have been 1,114 deaths due to this virus as of the reporting date. (Source:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/)

Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.  Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

To learn more about Ovation Science, please visit:

www.ovationscience.com for corporate information

www.InvibeMD.com or connect with Invibe MD on Facebook, Instagram and Twitter.

www.ArloCBDBeauty.com or connect with ARLO on Facebook, Instagram and Twitter.

 

About Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal cannabis and hemp formulations made with patented Invisicare® skin delivery technology. The technology enhances the delivery of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal cannabis products incorporating CBD, THC and combination products along with a line of anti-aging / beauty products made with CBD. Ovation’s business model is to develop and market its two product lines ARLO CBD Beauty and Invibe MD, our health and wellness line, as well as continuing to out-license its topical and transdermal formulations to cannabis companies globally. Ovation formulated CBD and THC products are marketed in Nevada in state-approved dispensaries by its US licensee with additional states being added. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website ovationscience.com.

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

FOR INVESTOR RELATIONS

Doug Kerr:
📧 i[email protected]
+1 (604) 315-4400

 

CONTACT:

 

FOR INVESTOR RELATIONS:
Doug Kerr:
[email protected]
Phone: 604.315.4400
FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:
Doreen McMorran
[email protected]
Phone: 604-283-0903 ext. 4
Copyright © 2020 OVATION Science Inc., All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:

OVATION Science Inc.

Suite 510-744 West Hastings Street

Vancouver, BCV6C 1A5

Canada

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading